Senti Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Senti Biosciences (SNTI).

Price Target Range — 6 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$11Upside to Avg. PT+6347.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 15, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$11→$12
Mar 30, 2026	Chardan Capital	Geulah Livshits	PT Cut	Buy	$13→$11
Dec 9, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$12→$13
Nov 21, 2025	Leerink Partners	Jeffrey La Rosa	Initiate	Outperform	$6
Oct 14, 2025	HC Wainwright & Co.	Emily Bodnar	Initiate	Buy	$12
Aug 8, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Jun 12, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Jun 6, 2025	Laidlaw & Co.	Yale Jen	Initiate	Buy	$5
May 2, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Dec 4, 2024	Chardan Capital	Geulah Livshits	PT Raise	Buy	$10→$12
Dec 2, 2024	Chardan Capital	Geulah Livshits	Maintained	Buy	$10

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Outperform rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.

Benzinga Newsdesk

Senti Biosciences Holdings Inc

Senti Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

People Also Watch

People Also Watch

Senti Biosciences Holdings Inc

Senti Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROChardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PROChardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PROChardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PROLeerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PROHC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PROChardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target